Brain Cancer Pipeline

About Origenis

Origenis is a private, preclinical-stage biotech firm utilizing an integrated AI and wet-lab platform to pioneer small molecule therapeutics for underserved diseases. Its core technology, featuring components like Cippix®, MolMind®, and MOREsytem®, enables the design and optimization of novel compounds with a focus on tissue-specific delivery, particularly to the brain and eye. The company has established early validation through historical and potentially ongoing collaborations with entities like Vivoryon and Alcon, and is advancing internal pipelines in neurodegeneration, brain cancer, and ophthalmology.

Therapeutic Areas

Other Brain Cancers Drugs